logo

Cathay Industrial Biotech (CBIO)



Trade CBIO now with
  Date
  Headline
5/3/2018 8:18:11 AM Catalyst Biosciences Q1 Net Loss Attributable To Common Stockholders $5.0 Mln Or $0.56/Shr
4/12/2018 8:17:54 AM Catalyst : S. Korea Oks Addition Of Sixth Cohort To Phase 1/2 Trial Of CB 2679d/ISU304 In Individuals With Hemophilia
3/1/2018 8:50:08 AM Catalyst Biosciences FY Net Loss Attributable To Common Stockholders $25.5 Mln Or $7.45 Per Share
2/26/2018 8:19:32 AM Catalyst Plans To Initiate Phase 2b Study Of CB 2679d In Q3 2018
2/9/2018 7:32:56 AM Catalyst Biosciences Reports Positive Top-Line Data From Phase 1/2 Study Of Subcutaneous CB 2679d/ISU304
1/4/2018 8:08:26 AM Catalyst Biosciences Begins Phase 2/3 Trial Of Marzeptacog Alfa For Prophylaxis In Hemophilia A Or B With Inhibitors
12/22/2017 12:38:16 PM Catalyst Biosciences Announces Closing Of Public Offering Of Common Stock
12/18/2017 8:16:32 AM Aduro Biotech Announces Initiation Of Phase 1/2 Clinical Trial Of BION-1301
12/14/2017 8:32:44 AM Catalyst Biosciences Appoints Edward Williams To The Board
12/8/2017 11:29:08 AM B. Riley Initiates Catalyst Biosciences Inc. (CBIO) At Buy With $19 Price Target
11/28/2017 8:42:01 AM Catalyst Biosciences Appoints Arwa Shurrab VP Of Regulatory Affairs And Jamie Ellen Siegel Head Of Clinical Development
9/26/2017 8:03:44 AM Catalyst Biosciences Granted FDA ODD For Subcutaneous Recombinant Human Factor IX Variant For Hemophilia B
9/25/2017 8:08:38 AM Catalyst Biosciences Completes First Subcutaneous Dosing Cohort In Ongoing Hemophilia B Clinical Trial